I’ve been driving the Suzuki e Vitara – here’s my honest review

Bags of charm, but behind the times on tech - Suzuki reinvents its 90s icon as an appealing SUV that feels like it’s still a ...

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, ...

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic ...

Parsons Reports Third Quarter 2025 Results

Q3 2025 Financial Highlights . Q3 revenue of $1.6 billion decreased 10% year-over-year and 14% on an organic basis; Revenue growth of 14% excluding confidential contract; 9% on an ...

MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody Sonelokimab

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to pr ...